Euroscreen SA Today Announced the Appointment of Graeme Fraser, Ph.D. as Director of Drug Discovery

Euroscreen SA today announced the appointment of Graeme Fraser, Ph.D. as Director of Drug Discovery.

Brussels, Belgium (PRWEB) July 16, 2007 -- Euroscreen SA today announced the appointment of Graeme Fraser, Ph.D. as Director of Drug Discovery.

Dr. Fraser will be responsible for directing the research and development programs at Euroscreen, focused on drug discovery. As a result of the progress we made over the past three years, Euroscreen is now entering a new phase in its development whereby it will validate proprietary drug targets and intensify drug discovery activities. Dr. Fraser's skill set in this area will greatly contribute to our transition to a drug development company.

"We are delighted that Graeme has joined Euroscreen as a key member of our executive team," stated Jean Combalbert, CEO of Euroscreen. "Graeme brings invaluable experience to the organization that will be essential for building a successful company and improving the productivity of our drug discovery process."

Before joining Euroscreen, Dr. Fraser's most recent position was as the VP, Drug Discovery at Tranzyme, Inc. for five years. Prior to Tranzyme, Dr. Fraser spent two years in charge of preclinical development at Viron Therapeutics Inc., and five years at AstraZeneca, Canada, working in in vivo pharmacology. Dr. Fraser holds a Ph.D. from Mc Gill University, Canada. "I am excited to take on the challenge of Director of Drug Discovery at Euroscreen", said Graeme Fraser. "Euroscreen has the GPCR science and technologies to become a powerhouse in drug discovery, and I look forward to making that work."

About Euroscreen SA - www.euroscreen.com
Euroscreen, a privately held company based in Brussels, Belgium, is a preclinical-stage biopharmaceutical company focusing on the discovery, development and partnering of small molecule drugs for unmet medical needs. Euroscreen is developing a pipeline of compounds targeting G protein-coupled receptors (GPCRs) using over 12 years of experience in research and commercialization of this critical class of drug targets. Initially, Euroscreen was a spin-off company of the "Université Libre de Bruxelles" based on GPCRs reagents development and commercialization. Euroscreen is now developing internal targets such as CCR5 and multiple additional targets as well as several preclinical-stage collaborations with partners.                                                    .

The Company has developed a broad target portfolio for licensing to biopharmaceutical companies. Such patents address GPCRs such as CCR5, Chemerin receptor, GPR43, GPR7/8, FPRL2, purinergic receptors (P2Y4, P2Y11 and P2Y13) and SHIP2 for type II diabetes. Euroscreen is able to offer intellectual property rights to companies for the development of therapeutic drugs that act through these targets.                            

Euroscreen pursues a dual platform strategy of combining its drug discovery business with its custom services business, including its custom screening services (EuroSCREEN FAST™), GPCR antibody development and other services to serve biotech and pharmaceutical companies around the world. The company has research and licensing partnerships with Alchemia, Cephalon, GNF, HGS, ICOS, Medarex, Novartis and Pfizer Inc.

###